Ocular adverse events of cenegermin used in neurotrophic keratopathy: an analysis of the FDA adverse event reporting system database

References

• Brzheskiy VV, Popov VY, Efimova EL, et al. [Modern capabilities in diagnosis and treatment of neurotrophic keratopathy]. Vestn Oftalmol. 2022;138(6):123–132. doi: 10.17116/oftalma2022138061123
   PubMedGoogle Scholar
• Dua HS, Said DG, Messmer EM, et al. Neurotrophic keratopathy. Prog Retin Eye Res. 2018 Sep;66:107–131.
   PubMed Web of Science ®Google Scholar
• Weiss M, Molina R, Ofoegbuna C, et al. A review of filamentary keratitis. Surv Ophthalmol. 2022 Jan;67(1):52–59. doi: 10.1016/j.survophthal.2021.04.002
   PubMed Web of Science ®Google Scholar
• Schilimow A, Wiechens B. Botulinum toxin a induced protective ptosis for the treatment of recurrent epithelial defects in neurotrophic keratopathy. Ophthalmologe. 2017 Aug;114(8):745–747. doi: 10.1007/s00347-016-0377-7
   PubMed Web of Science ®Google Scholar
• Kolli S, Bojic S, Ghareeb AE, et al. The role of nerve growth factor in maintaining proliferative capacity, colony-forming efficiency, and the limbal stem cell phenotype. Stem Cells. 2019 Jan;37(1):139–149. doi: 10.1002/stem.2921
   PubMed Web of Science ®Google Scholar
• Deeks ED, Lamb YN. Cenegermin: a review in neurotrophic keratitis. Drugs. 2020 Apr;80(5):489–494. doi: 10.1007/s40265-020-01289-w
   PubMed Web of Science ®Google Scholar
• Adams BS, AR P. Cenegermin. Treasure Island (FL): StatPearls; 2023.
   Google Scholar
• FDA approves first drug for neurotrophic keratitis, a rare eye disease [Internet]. FDA; 2020 [cited Jul 23, 2023]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-neurotrophic-keratitis-rare-eye-disease
   Google Scholar
• Bonini S, Lambiase A, Rama P, et al. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmol. 2018 Sep;125(9):1332–1343. doi: 10.1016/j.ophtha.2018.02.022
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Massaro-Giordano M, Perez VL, et al. Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: a multicenter randomized vehicle-controlled pivotal trial. Ophthalmol. 2020 Jan;127(1):14–26. doi: 10.1016/j.ophtha.2019.08.020
   PubMed Web of Science ®Google Scholar
• Bonini S, Lambiase A, Rama P, et al. Phase I Trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmol. 2018 Sep;125(9):1468–1471. doi: 10.1016/j.ophtha.2018.03.004
   PubMed Web of Science ®Google Scholar
• White CA, Affeldt J. Topical cenegermin associated ocular surface and contact lens drug precipitate deposit formation. Am J Ophthalmol Case Rep. 2022 Sep;27:101584. doi: 10.1016/j.ajoc.2022.101584
   PubMedGoogle Scholar
• Pedrotti E, Bonacci E, Chierego C, et al. Eight months follow-up of corneal nerves and sensitivity after treatment with cenegermin for neurotrophic keratopathy. Orphanet J Rare Dis. 2022 Feb 21;17(1):63. doi: 10.1186/s13023-022-02237-5
   PubMed Web of Science ®Google Scholar
• Qureshi S, Ferguson TJ, Lim M, et al. Acute calcific band keratopathy as an adverse effect of recombinant human nerve growth factor (cenegermin): a multicenter case series. Cornea. 2022 Jan 1;41(1):52–59. doi: 10.1097/ICO.0000000000002767
   PubMed Web of Science ®Google Scholar
• Weinlander E, Ling J, Reddy A, et al. Epithelial plague formation secondary to recombinant human nerve growth factor. Cornea. 2020 Sep;39(9):1174–1176. doi: 10.1097/ICO.0000000000002300
   PubMed Web of Science ®Google Scholar
• Shu Y, Ding Y, Dai B, et al. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system. Expert Opin Drug Saf. 2022 Apr;21(4):563–572. doi: 10.1080/14740338.2022.2016696
   PubMed Web of Science ®Google Scholar
• Lu W, Sun S, Wei J, et al. Dipeptidyl peptidase-4 inhibitors and risk of venous thromboembolism: data mining of FDA adverse event reporting system. Int J Clin Pharm. 2020 Oct;42(5):1364–1368. doi: 10.1007/s11096-020-01037-w
   PubMed Web of Science ®Google Scholar
• Shu Y, He X, Wu P, et al. Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022;10:996179. doi: 10.3389/fpubh.2022.996179
   PubMed Web of Science ®Google Scholar
• Guo H, Wang B, Yuan S, et al. Neurological adverse events associated with esketamine: a disproportionality analysis for signal detection leveraging the FDA adverse event reporting system. Front Pharmacol. 2022;13:849758. doi: 10.3389/fphar.2022.849758
   PubMed Web of Science ®Google Scholar
• Kinoshita S, Hosomi K, Yokoyama S, et al. Time-to-onset analysis of amiodarone-associated thyroid dysfunction. J Clin Pharm Ther. 2020 Feb;45(1):65–71. doi: 10.1111/jcpt.13024
   PubMed Web of Science ®Google Scholar
• Van Holle L, Zeinoun Z, Bauchau V, et al. Using time-to-onset for detecting safety signals in spontaneous reports of adverse events following immunization: a proof of concept study. Pharmacoepidemiol Drug Saf. 2012 Jun;21(6):603–610. doi: 10.1002/pds.3226
   PubMed Web of Science ®Google Scholar
• Scholl JH, van Puijenbroek EP. The value of time-to-onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands. Pharmacoepidemiol Drug Saf. 2016 Dec;25(12):1361–1367. doi: 10.1002/pds.4115
   PubMed Web of Science ®Google Scholar
• Dandar RA, Schiffbauer J, Cheung AY. Late-onset diffuse lamellar keratitis after treatment with cenegermin. Can J Ophthalmol. 2022 Dec;57(6):e202–e204. doi: 10.1016/j.jcjo.2022.02.011
   PubMed Web of Science ®Google Scholar
• Kanu LN, Ciolino JB. Nerve growth factor as an ocular therapy: applications, challenges, and future directions. Semin Ophthalmol. 2021 May 19;36(4):224–231. doi: 10.1080/08820538.2021.1890793
   PubMed Web of Science ®Google Scholar
• Dompé. Oxervate: EPAR - Product information [Internet]. European Medicines Agency; 2023 [cited Jul 23, 2023]. Available from: https://www.ema.europa.eu/en/documents/product-information/oxervate-epar-product-information_en.pdf
   Google Scholar
• EMA. Oxervate : EPAR - Public assessment report [Internet]. European Medicines Agency; 2017 [cited Jul 23, 2023]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/oxervate-epar-public-assessment-report_en.pdf
   Google Scholar